Biological Safety Evaluation of 99mTc-DTPA-Ketoconazole for Diagnosis of Fungal Infection by Sriyani, Maula Eka et al.
 1 
 
 
Biological Safety Evaluation of 99mTc-DTPA-Ketoconazole for Diagnosis of 
Fungal Infection 
Maula Eka Sriyani, Hendris Wongso, Eva Maria Widyasari, Rizky Juwita 
Sugiharti, Iim Halimah, Iswahyudi, Ahmad Sidik, Epy Isabela, Witri Nuraeni  
National Nuclear Energy Agency (BATAN), Jl. Tamansari No. 71 Bandung, 
40132, Indonesia 
Abstract Infectious diseases have become one of the leading cause of mortality around the world, including in the 
Southeast Asia. One of the microbial that cause infection is fungi. Occasionally, deep-seated fungal infection is difficult 
to detect using conventional diagnosis methods and therefore leads to inaccurate detection. Our previous research was 
conducted in order to obtain the labeled compound of 99mTc-DTPA-Ketoconazole with a high radiochemical purity 
(98.40 ± 0.86%). Moreover, the in-vitro assays showed that 99mTc-DTPA-Ketoconazole can potentially bind to Candida 
albicans. On the other hand, in clinical routine use, diagnostic kit should be safe for the patients. Consequently, this 
research was conducted to determine the biological safety parameters of 99mTc-DTPA-Ketoconazole on the animal 
study, including single dose and acute toxicity test, sterility, and apirogenicity test. The results showed that both the 
single dose at 34.6 μCi and dose until 149 times of the single dose did not stimulate the toxic response to the animals. In 
addition, the sterility data revealed that there was no microbial growth after 7 days of incubation at 37°C as well as 
fungal growth after 14 days of incubation at 25°C. Furthermore, the apirogenicity test using rabbits revealed that there 
was no increase in temperature more than 0.6°C for each animal and not more than 1.5°C of total increase of 
temperature for all the animals. It is concluded that the 99mTc-DTPA-Ketoconazole is satisfy the requirements of 
biological safety of a radiopharmaceutical and therefore was acceptable for fungal detection in nuclear medicine. 
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1. INTRODUCTION 
Organisms invade the human body, 
attach to cells, multiply, and cause certain 
disease (Anonim, 2011). Recently, infectious 
diseases have become one of the major health 
problem that cause mortality worldwide. 
According to WHO data in 2012, about 9.5 
million death was caused by infectious 
diseases in parts of Africa, Southeast Asia, 
and the Middle East region (Foxman, 2011). 
Infectious diseases can also reduce the level 
of productivity of a person. A major factor 
that cause infectious diseases become difficult  
to be cured is the difficulty to determine the 
presence of pathogens, especially in deep-
seated infections. Specifically, one of 
pathogenic fungi that may generate deep-seated 
infection is C. albicans which is the normal flora 
that usually can be found in the mucous 
membranes of the respiratory tract, 
gastrointestinal tract, and vagina. In some cases, 
if the amount of C.albicans is excessive, it can 
cause numerous diseases, such as canker sores, 
intestinal candidiasis, vaginal candidiasis, and 
systemic candidiasis (Tjay, 2007). 
One of the drugs of choice which is widely 
used to treat the fungal infections including 
C.albicans and some other microbes is 
ketoconazole. Chemically, ketoconazole is an 
imidazole derivative that has the mechanism of 
action by binding directly to the cytochrome 
P450 enzyme and inhibit the synthesis of 
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ergosterol which is necessary to the formation 
of fungal cell membranes, thus cause lysis of 
the fungal membranes. Moreover, 
ketoconazole is also act as an antimitotic and 
a weak bacteriostatic agent for gram-positive 
bacteria (Tjay, 2007). Based on the molecular 
structure of ketoconazole (Fig.1), it has a 
functional group that allows it to be labeled 
with a radionuclide, such as technetium-99m 
(99mTc) leads to a promising 
radiopharmaceutical for detecting C.albicans. 
Recently, 99mTc is the common radionuclide 
used in nuclear medicine for imaging several 
diseases and is contributed to 80-85% of 
clinical applications, especially for diagnosis 
as 99mTc has some advantages such as the 
ideal half-life (6.0 hours) and emits pure 
gamma ray (γ) with energy of 140 KeV 
(Verbruggen, 2007). 
 
Figure 1. Chemical structure of Ketoconazole 
(Oh et al., 2012). 
More importantly, the gamma energy of 
99mTc does not stimulate any cell damages in 
human. Therefore, in clinical routine use, 
99mTc can be administrated by direct injection 
even with dose over 30 mCi without 
significant radiation effect to the patient. 
Moreover, its energy property makes it 
suitable for studying the organs, which is 
located deep in the body. In addition, a 
primary advantange of 99mTc is it can bind to 
a numerous of organic molecules which have 
an electron donor group (Zolle, 2007; 
Schwochau, 2000; Saha, 2010; Owunwanne, 
1995). Some studies demonstrated that 99mTc 
still become a primary radiotracer in nuclear 
medicine, especially for imaging infectious 
diseases. Recently, Welling, et al. reported 
several radiopharmaceutical that potentially used 
to detect infections (Welling., 2009). In addition, 
several studies reported that 99mTc as an imaging 
agent for infections have used in some cases 
(Dass et al., 2002), for instance, by Awaludin 
and colleagues (Awaludin, 2011). In their 
review, they showed that 99mTc is widely used in 
nuclear medicine, including for imaging 
infectious diseases. Moreover, Motaleb 
(Motaleb., 2011) in 2011 revealed the potential 
use of 99mTc-gatifloxacin and 99mTc-Cefepime 
for imaging bacterial infections. Similarly, over 
the last decade, some imaging agents have 
developed to detect the fungal infections, such as 
99mTc-Ciprofloxacin (Nurlaila et al., 2005), 
99mTc-aptamers (Roberta et al., 2015), 99mTc-
Ceftriaxone (Kaul et al., 2013), and 99mTc-
Danofloxacin (Moustapha, 2016). Some of these 
radiopharmaceuticals showed a specific 
detection for bacterial infection or sterile 
inflammation, however (Moustapha, 2016) less 
specific for detecting fungal infections. More 
recently, in 2014 99mTc-caspofungin was also 
developed for the diagnosis of fungal infections 
(Yazdani et al., 2014). 
Studies suggested that Ketoconazole will 
interact with fungi in the area of infection, while 
radionuclide 99mTc will emit γ radiation during 
the imaging process and will be directly 
captured by the gamma camera from outside the 
body. The rapid and accurate diagnosis are 
necessary because of the death by the infection 
often caused by the failure or delay in the 
process of diagnosis, so it leads to the ineffective 
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treatment. The labelling techniques of 99mTc-
DTPA-Ketoconazole (Sriyani, 2013) have 
been conducted by our groups and provides 
the high radiochemical purity. Subsequently, 
99mTc-DTPA-Ketoconazole will undergo a 
quality control. This procedure is divided into 
two categories: the determination of 
physicochemical properties and biological 
safety determination which includes the 
toxicity (Halimah et al., 2009), sterility, and 
apirogenity (Saha, 2010). Physicochemical 
properties determination (Sriyani, 2013) has 
been conducted in the previous studies, as 
well as biological study such as microbial 
uptake (Sriyani et al., 2015). Therefore, the 
purpose of this study was to determine the 
biological safety aspect of 99mTc-DTPA-
Ketoconazole to fulfil the safety aspect 
requirement of a diagnostic kit for patients. 
2. MATERIALS AND METHODS 
2.1 Materials 
Ketoconazole (obtained from the School 
of Pharmacy, ITB), Diethylene triamine Penta 
Acetate (DTPA), Na99mTcO4 (ANSTO), NaCl 
0,9% (IPHA), aquabidest sterile pro-injection 
(IPHA), HCl (E. Merck), NaOH (E. Merck), 
alcohol 70%, nutrient agar medium (Oxoid, 
England), saboroud agar (Merck, Germany) 
and thioglycolic liquid (Merck, Germany) for 
the sterility test. 
This study was used two types of 
animals which are white mice (Mus 
musculus) Swiss strain and rabbits. White 
male mice 4-5 weeks old with the weight of 
30-40 grams were used for toxicity test, while 
the white rabbit 2-3 months old with the 
weight of 2-3 kg were used for apirogenicity 
test. The use of both types of animals based 
on the methods as outlined in the Indonesian 
Pharmacopoeia Edition V as well as the general 
procedure for radiopharmaceutical quality 
controls. The use of animals in this study has 
been approved by animal ethics committee 
(KEPPHP) BATAN No. 001 / KEPPHP-
BATAN / IV / 20I4. 
The equipments used in this study were 
syringe 1 mL, thermocouple, rabbit restrainer, 
analytical balances (Mettler Toledo), laminar 
airflow (BBL Biological Cabinet), incubator 
(Memmert), Single Channel Analyzer (Ortec) 
and Dose Calibrator (Victoreen), autoclave 
(Hirayama), vortex mixer, test tubes, petri 
dishes, syringe filters, test tube rack, micro 
pipette (Eppendorf) and needle ose. 
2.2 Methods  
a. Toxicity test 
A single dose toxicity and acute toxicity 
test were carried out in this study. These 
procedure are performed based on the guidance 
from the Indonesian Pharmacopoeia. In single 
dose toxicity test, 34.6 μCi of 99mTc-DTPA-
Ketoconazole was injected intravenously per 
mouse (5 mice in total). For acute toxicity test, 
the dose of 99mTc-DTPA-Ketoconazole was 
increased up to 150 times of the single dose. The 
results are acceptable if there is no animals 
become sick or die at the end of 48 hours after 
injection, or no more than an animal shows any 
unusual symptoms or behaviour. If one or more 
animals die or if more than one animal show 
abnormal toxicity symptoms or behaviour, the 
experiment should be repeated using at least 10 
mice. If the animals do not demonstrate any 
symptoms of abnormality at the end of 48 hours 
after injection, the observation was continued for 
up to 7 days, and then continued until 14 days 
(Kementerian Kesehatan Republik Indonesia, 
2014). 
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b. Sterility test 
Direct inoculation test method used in 
this study. The test was conducted on the 
clean laminar airflow that has been sterilized 
prior to use. DTPA-Ketononazole kit was 
prepared by adding 2 mL of sterile 
physiological saline into the DTPA-
Ketononazole kit and then shaken until 
homogeneous. Three types of media were 
used in this test, which are liquid thioglycolic, 
saburoud agar, and nutrient agar. Liquid 
thioglycolic in the test tubes was opened near 
the flame of the bunsen, 20 mL of the kit was 
added, then closed with cotton lid. To the 
nutrient agar and Saboroud agar in each petri 
dish was poured 1 mL of DTPA-
Ketononazole. Each test was performed a 
total of three times (triplo). As controls, the 
test tube contains thioglycolic liquid, a petri 
dish containing nutrient agar, and a petri dish 
containing saboroud were opened and placed 
in a laminar airflow during the test. 
Subsequently, liquid thioglycolics and 
nutrient agars containing samples were 
incubated in an incubator at 37°C for 14 days, 
while the saboroud agars were incubated at 
room temperature (25°C) for 14 days. 
Bacterial and fungal growth were observed 
daily for 14 days by observing the presence of 
contaminants (colony) of bacteria or fungi on 
agar medium and the change of turbidity in 
thioglycolic medium (Kementerian Kesehatan 
Republik Indonesia, 2014). 
c. Apirogenicity test 
Apirogenicity test was conducted as 
outlined in the Indonesian Pharmacopoeia V 
and general procedures radiopharmaceutical 
quality control (Kementerian Kesehatan 
Republik Indonesia, 2014; Anonymous, 
2008). This test was carried out using three 
rabbits and was measured by the change of 
rabbits temperature. The temperature of each 
rabbit was measured by inserting a thermocouple 
probe that has been smeared with lubricant, into 
the anus of rabbits with a depth of ± 2 cm to 
obtain a constant temperature. The initial 
temperatures of rabbits were determined at 30 
minutes before the injection of the 
radiopharmaceutical. Subsequently, 99mTc-
DTPA-Ketocononazole was injected 
intravenously through the auricular vein in the 
rabbit ears. Rabbits temperature were measured 
again at the 0, 60, 120, and 180 minutes (interval 
60 minutes after injection). The highest 
temperature obtained starting from the 60 minute 
after injection until minute 180 was called the 
maximum temperature. 
The calculation of the temperature change 
is determined by using equation (1) below: 
T initial = T at 30 '(1) 
T maximal response = T - T initials (2) 
• The temperature of the initial (T initials): the 
temperature at 30 minutes before the 
injection. 
• Maximum Temperature (T maximum): The 
highest temperature on the measurement of 3 
hours after injection. 
• Temperature response (T response): the 
difference between the T maximum and T 
initials. 
3. RESULSTS AND DISCUSSION 
Radiochemical purity is one of the 
important characteristics of a 
radiopharmaceutical. As a fundamental 
procedure in nuclear medicine, the 
radiochemical purity of a radiopharmceutical for 
clinical application should be 95% or higher 
[19]. In this study, the radiochemical purity of 
99mTc-DTPA-ketoconazole was obtained at 
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98.40 ± 0.86% and therefore is acceptable as 
an approriate radiopharmaceutical for further 
biological analysis. Furthermore, the toxicity 
test was also conducted to determine the 
toxicity properties of 99mTc-DTPA-
Ketononazol in humans or animals. To obtain 
equivalent pharmacological effects of a 
radiopharmaceutical in every species of 
animal, it is necessary to determine a data 
regarding the use of quantitative dose [25]. 
Therefore, in this study, the conversion dose was 
calculated for every specific animal. In this case, 
the dose of the radiopharmaceutical for the 
human need to be converted to animal dose 
according to the body surface area comparisons 
(Table 1). 
Table 1. The conversion of the dose based on body surface area (Juwita et al., 2007) 
 
Mice Mouse  Rabbit Human 
Mice 
1.0 7.0 27.8 387.9 
Mouse 
0.14 1.0 3.3 56.0 
Rabbit  
0.04 0.25 1.0 14.2 
Human  
0.0026 0.018 0.07 1.0 
 
Based on table 1, it can be calculated 
that the dose conversion factor for sub-
chronic toxicity test of 99mTc-DTPA-
Ketoconazole is 0.0026 times lower than the 
dose administrated to humans. Based on this 
calculation, a single dose was administrated 
to each animal at 34.6 μCi. 
Toxicity test was conducted in a single-
dose toxicity for sub-chronic toxicity and 
acute toxicity test. In this test, three healthy 
white mice (M. musculus) strain Swiss was 
used. The observation of a single dose sub-
chronic toxicity test such as mortality, appetite, 
behavior disorders, eye color, fur condition, and 
animal activities did not show any evidence of 
abnormality. Similarly, the increasing of dose 
until 150 times from initial dose showed 
negative toxicity behaviours. For detail, the 
acute toxicity test results are shown in Table 2. 
Overall, this data suggest that 99mTc-DTPA-
Ketokonazole demonstrates non-toxic effects on 
animals.
 
Table 2. The observation of acute toxicity of 99mTc-DTPA-Ketoconazole 
Dose increased Initial condition post injection Condition of 24 hours post 
injection 
2.0 Normal Normal 
7.2 Normal Normal 
17.3 Normal Normal 
39.0 Normal Normal 
65.5 Normal Normal 
149.1 Normal Normal 
In clinical application, 99mTc-DTPA-
Ketoconazole should be administered 
parenterally. Therefore, this 
radiopharmaceutical must be sterile and not 
contain pyrogens. The sterility data observations 
can be seen in Table 3. It can be seen that 99mTc-
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DTPA-Ketokonazole is sterile, as evidenced 
by the absence of either the growth of 
bacteria and fungi (fungi) after incubation up to 
14 days. 
 
Table 3. Sterility test of 99mTc-DTPA-Ketoconazole 
Sample  
Testing 
medium  
Day of observations 
0 2 4 6 8 10 12 14 
99mTc-DTPA-
Ketokonazol 
Nutrient Agar - - - - - - - - 
- - - - - - - - 
Thioglicolic  - - - - - - - - 
- - - - - - - - 
Control 
 - - - - - - - - 
(-)  = No microbial growth  
(+) = Microbial growth 
The other requirement for an appropriate 
radiopharmaceutical in clinical use is the 
absence of pyrogen. Pyrogens are defined as 
metabolic outcomes from the living or dead 
microorganisms which cause specific pyretic 
response after the injection of a 
radiopharmaceutical. As the pyrogens are 
water-soluble, the sterilization process with 
steam under pressure and filtration through a 
syringe filter may be unuseful, although this 
process can eliminate the microorganisms. 
Pyrogenic reactions in the human body are 
indicated by the fever and chills symptoms 
soon after the injection or between 45 to 90 
minutes after injection of the 
radiopharmaceutical. Therefore, the presence of 
pyrogens is not allowed in a 
radiopharmaceutical. In this study, we 
determined the presence of pyrogens using 
healthy rabbits. The temperature changes were 
observed in rabbits after injection of the 
radiopharmaceutical. Before the injection of the 
radiopharmaceutical, the temperature of rabbits 
were measured as the initial temperature. The 
body temperature measurement is carried out by 
a thermocouple into the rectum of rabbits at 1-2 
cm deeps. Before used, probe should be smeared 
with the commercial lubricant to avoid irritation 
when the probe entering the anus (Hendris, 
2013). Pyrogen test results are shown in Table 4. 
Table 4. Pyrogenic test of 99mTc-DTPA-Ketokonazol 
No. Rabbit Initial temp. 
(°C) 
Rabbit Temperature (° C) Observed at Time- 
30 60 90 120 150 180 
I 39.3 39.4 39.4 39.3 39.3 38.6 39.1 
II 39.2 39.4 39.5 39.5 39.4 39.0 38.5 
III 38.9 39.3 39.4 39.5 39.5 39.0 38.9 
Total increase 
of temperature 
 
0.7 0.9 0.9 0.8 -0.8 -0.9 
Note: total temperature increase from all of the rabbits not more than 1.5° C and none of the rabbits having 
the increasing temperature >0.6°C while observation.
Based on the observation, the increasing 
of temperature from all of the rabbits after the 
injection is not more than 1.5°C; and the 
increase of temperature for each rabbits is below 
0.6°C. Therefore, this data indicates that this 
radiopharmaceutical was free from pyrogenic 
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substances. 
4. CONCLUSION 
This study suggests that 99mTc-DTPA-
Ketoconazole demonstrated negative 
toxicological effect to the animals in a single 
dose as well as acute toxicity test. The 
pyrogenic test also showed no negative 
response (increasing of temperature) due to 
the administration of radiopharmaceuticals. In 
addition, all the radiopharmaceutical kits are 
sterile as evidenced by the absence growth of 
the microorganism in the mediums. It can be 
concluded that 99mTc-DTPA-ketoconazole is a 
non-toxic radiopharmaceutical. It can be 
prepared as a sterile agent, and free of 
pyrogenic substances, and therefore 
appropriate for further biological analysis. 
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